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Abstract The distribution and function of T lymphocytes in
human lung cancer remain limited. In this study, we investigat-
ed the properties of human T cell subsets in the blood of non-
small cell lung cancer (NSCLC) patients. We found a relatively
normal level of CD4+ subsets in the blood of NSCLC patients,
but CD8+ effector Tcells increased and CD8+ effector memory
cells declined compared to the healthy donors. To further ana-
lyze their properties, we stimulated the peripheral blood mono-
nuclear cells (PBMCs) of NSCLC patients by mitogens to ex-
amine cytokine production. Our data suggest that both CD4+
and CD8+ naïve cells in NSCLC patients significantly reduced
IFN-γ and TNF-α production. Additionally, fewer CD8+ ef-
fector cells produced IFN-γ and TNF-α in NSCLC patients
than in healthy subjects. Moreover, similar results were ob-
served for CD4+ or CD8+ memory cells in NSCLC patients
for the production of IFN-γ, TNF-α, and IL-17. Therefore, our
results strongly suggest that the function of CD4+ and CD8+ T
lymphocytes in NSCLC patients is compromised or dysregu-
lated. The development of vaccines and antitumor immunother-
apy may be essential for the treatment of lung cancer patients.
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Introduction
Immunological memory is critical for long-term immunity and
protection from infection. After naïve Tcells are activated by the
antigen, naïve Tcells differentiate into effector Tcells, depending
on the anatomical position and phenotypic characteristics; effec-
tor T cells display different functions [1]. However, only a small
fraction of effector T cells becomes long-lived memory T cell to
provide lifelong protection against the previously encountered
pathogens [2, 3]. With respect to the tissue homing-related mo-
lecular expression, memory T cells can be divided into two cat-
egories, central memory T cells (Tcm) and effector memory T
cells (Tem) [4]. Recent data revealed that adoptively transferred
different subsets of memory T cells have different antitumor
activity in mouse models [5]. The distribution and function of
human memory T cells have been identified in healthy subjects
[6], but the physiological distribution and function of human T
cell subsets in lung cancer are still limited. Clearly, the under-
standing of the compartmentalization of memory T cell subsets
will provide valuable basis for designing tumor immunotherapy.
Current studies focus on the frequency of the tumor-
infiltrating lymphocytes (TILs) to predict the prognosis of
cancer patients [7]. The high frequency of CD4+ T cells in
TILs and malignant pleural effusions (MPEs) correlates with a
favorable prognosis in lung cancer patients [8, 9]; however,
other studies indicate that the high number of CD8+ T cells,
not CD4+ T cells, in TILs has a good clinical outcome
[10–12]. The distinct distribution of CD4+ and CD8+ T cell
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in TILs results in different clinical outcomes in lung cancer
patients. The presence of high density of CD3+CD8+
CD45RO+ immune cells within tumor region is correlated
with favorable clinical outcome in epithelial ovarian cancer
[13], while the number of effector CD8+ T cells in TILs de-
creased in lung cancer [14]. In our study, we assessed the
expression of memory T cell subsets in non-small cell lung
cancer patients, and herein, we show the distinct compartmen-
talization of naïve T cells (Tn), Tcm, Tem, and effector T cell
(Teff) subsets in non-small cell lung cancer (NSCLC). Our
results provide further information regarding the distribution
and function of CD4+ and CD8+ memory T cell subsets in
human NSCLC patients. These results will lead to a better
understanding of the biology of lung cancer.
Material and methods
Study participants
Eight NSCLC patients from the First Affiliated Hospital of
Sun Yat-Sen University of Guangzhou, China, were enrolled
in this study. The eight patients including three female and
five male have the age range from 41 to 78 years. The final
diagnosis of lung cancer was based on pathological evidence
(detected by histological staining), one case of stage IV, three
cases of stage III, two cases of stage II, and two cases of stage I
cancer (Table 2). Patients whose serology tested positive for
HIV, HBV, and HCV were excluded from the study. None of
the patients received cancer-related chemotherapy during the
period of collecting samples. The blood and lymph nodes
were collected from the same NSCLC patients. Eight healthy
donors were recruited for collecting blood (the age range from
18 to 40 years); healthy lymph nodes were taken from non-
lung cancer patients (the age range from 29 to 70 years). The
sex of the healthy donor control group and lung cancer group
samples was matched.
Isolation of peripheral blood mononuclear cells
and lymphocytes
The lymph nodes were maintained in cold Hanks’ buffer and
brought to the laboratory within 2–4 h after surgery. The
lymph nodes were cut into small pieces and mashed with cold
PBS, after which any residual tissue fragments were removed
using a strainer (70 μm) (BD Falcon, 352340). The suspen-
sion was centrifuged at 524×g for 10 min at RT. The pellets
were washed with PBS and then resuspended in complete
RPMI 1640 medium (Invitrogen, Grand Island, NY, USA,
cat. 11875093) supplemented with 10% heat-inactivated fetal
bovine serum (FBS; Invitrogen, Grand Island, NY, USA),
100 U/mL penicillin (cat. 15071163), 100 mg/mL streptomy-
cin (15071163), 2 mM L-glutamine (cat. 25030081), and
50 mM 2-mercaptoethanol (cat. 21985023; Invitrogen,
Grand Island, NY, USA). The peripheral blood mononuclear
cells (PBMCs) were isolated from sodium heparin-treated
blood obtained from healthy donors or the lung cancer pa-
tients by Ficoll-Hypaque (Tian Jin Hao Yang Biological
Manufacture Co., Ltd., China, cat. LTS1077) gradient centri-




The pooled PBMCs and lymph node cells from the
healthy donors and the lung cancer patients were stained
for flow cytometry. The following panel of mouse anti-
human mAbs, all purchased from BD Biosciences (San
Jose, CA, USA) or eBioscience (San Diego, CA, USA),
was used: anti-human CD3-APC.cy7 (BD, 557832, SK7),
anti-human CD4-Percp.cy5.5 (BD, 560650, RPA-T4),
anti-human CD45RA-FITC (eBioscience, 11-0458-42,
HI100), and anti-human CCR7-PE.cy7 (BD, 557648,
150503). The cell data were acquired using a 10-laser
Gallios (Beckman Coulter Inc., Brea, CA, USA) analyti-
cal flow cytometer. Unstained and single fluorochrome-
stained cells were used as controls to provide accurate
compensation and data analysis. The results were ana-
lyzed with Kaluza software.
Intracellular staining
The PBMCs and lymph node cells were incubated in 96-well
bottom plates at 2 × 106 cells per well in RP10 media (RPMI,
10% heat-inactivated FBS) alone or with phorbol 12-myristate
13-acetate (PMA) (20 ng/mL) plus ionomycin (1μg/mL) for 4
to 6 h at 37 °C in the presence of BFA (10 μg/mL). The cells
were harvested, washed with PBS, stained for the surface
phenotypic markers, and fixed at RT with 2% PFA. The cells
were then permeabilized (0.01% saponin), and the intracellu-
lar cytokines were stained using anti-human IFN-γ-V450
(BD, 560371, B27), anti-human IL-17A-PE (BD, 560486,
N49-653), and anti-human TNF-α-APC (eBioscience, 17-
7349-82, MAB11). All samples were analyzed using a
Beckman Gallios instrument. The data were analyzed using
the Kaluza software (Beckman Coulter Inc., Brea, CA, USA).
PMA (cat. 16561-29-8), ionomycin (cat. 10634), brefeldin A
(BFA) (cat. B7651), bovine serum albumin, and NaN3 were
all purchased from Sigma-Aldrich (St. Louis, MO, USA).
Statistical analysis
GraphPad Prism software version 5 was used for the statistical
analysis. The Mann–Whitney test (two-tailed) and non-paired
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Student’s t test were performed to identify significant differ-
ences. A value of p ≤ 0.05 was considered statistically
significant.
Results
The distribution of CD4+ and CD8+ T cell subsets
in human lung cancer
The eight lung cancer patients recruited to this study had been
diagnosed with NSCLC and were HIVand HBV negative and
free of other cancers. We obtained blood from healthy donors
(n = 8) and collected blood and lymph nodes (LNs) from lung
cancer patients. Healthy lymph nodes were taken from non-
lung cancer patients (n = 6).
To assess the distribution of the CD4+ and CD8+ T cell
subsets in human lung cancer, we analyzed the Tn, Tcm, Tem,
and Teff of the PBMCs from the healthy donors and NSCLC
patients by flow cytometry according to established surface
markers (Tables 1 and 2) [1, 2].
We gated the CD3+CD4+ T cells and CD3+CD8+ T
cells in the healthy donors and NSCLC patients. We
found that the frequency of CD8+ T cells increased in
blood (p = 0.0002) and lymph node (p = 0.022) from
NSCLC patients compared to the normal group, while
the frequency of CD4+ T cells declined in NSCLC-Ly
group (p = 0.022). The CD8+ T cells outnumbered the
CD4+ T cells in NSCLC-PBMC (p = 0.006); in Normal-
Ly, the CD4+ T cells outnumbered the CD8+ T cells
(p = 0.004) (Fig. 1a). In humans, the CD45RO isoform
is the marker that distinguishes between naïve and mem-
ory T cells. Naïve cells are CD45RA+ and CD45RO−,
while memory T cells are CD45RA− and CD45RO+.
We used the LN homing receptor CCR7 to define the
subsets of CD45RA+ and CD45RO+ T cells (Fig. 1b).
The analysis of the CD4+ T cell subsets indicated that
the peripheral blood and lymph node contained similar
frequencies and absolute count of the Tn, Tcm, Tem,
and Teff cell populations both in the healthy donors and
NSCLC patients (Fig. 1c). The CD8+ Teff cells predom-
inated in the peripheral blood, representing 50–70% of the
total CD8+ T cells. In the NSCLC patients, the proportion
and absolute count of the CD8+ Teff cells were higher in
NSCLC-PBMC (70%) than in HD-PBMCs (50%)
(Fig. 1c). In contrast, the frequency of CD8+ Tem cells
was lower in the blood of the NSCLC patients than in the
healthy donors (Fig. 1c). In the NSCLC patients, CD4+
Tem and CD8+ Teff cells predominated in the lymph node
(NSCLC-Ly) (Fig. 1c). The subtypes of the CD4+ and
CD8+ T cell differed in both the health donor and
NSCLC patient. Specifically, the frequencies of the
CD4+ Tn (p = 0.031) and Tcm cells (p = 0.0032) were
greater than those of the CD8+ T cells in the blood of the
NSCLC patients; the proportion of the CD4+ Tcm was
greater than that of the CD8+ Tcm cells both in blood
and lymph node from healthy donor and NSCLC patients
(Fig. 1d). In addition, the fraction of the CD8+ Teff cells
was higher than that of the CD4+ Teffs in the NSCLC-
PBMC (p = 0.0003), HD-PBMCs (p = 0.0004), Normal-
Ly (p = 0.0181), and NSCLC-Ly (p = 0.003) (Fig. 1d).
The percentage of Tem cells did not differ between the
CD4 and CD8 groups in HD-PBMC, Normal-Ly, and
Table 1 Marker of human primary lymphocyte subsets for flow
cytometry
Subsets Donors (n) Surface marker
CD4+ naive 6–8 CD4+CCR7+CD45RA+CD45RO
CD4+ Tcm 6–8 CD4+CCR7+CD45RA−CD45RO+
CD4+ Tem 6–8 CD4+CCR7−CD45RA−CD45RO+
CD4+ Teff 6–8 CD4+CCR7−CD45RA+CD45RO
CD8+ naive 6–8 CD8+CCR7+CD45RA+CD45RO
CD8+ Tcm 6–8 CD8+CCR7+CD45RA−CD45RO+
CD8+ Tem 6–8 CD8+CCR7−CD45RA−CD45RO+
CD8+ Teff 6–8 CD8+CCR7−CD45RA+CD45RO−
Eight human lymphocyte subsets from normal peripheral blood lympho-
cytes (n = 8), lung cancer peripheral blood lymphocytes (n = 8), normal
lymph nodes (n = 6), and lung cancer lymph nodes (n = 8) gated by
various surface marker combinations
















Eight lung cancer patients which comprise
five males and three females from 41 to
78 years of age were recruited in this
study; all cases were newly diagnosed
and had not received anticancer therapy.
The study was approved by the Sun Yet-
San University ethics committee. Four
cases were adenocarcinoma of lung cancer
and four cases squamous carcinoma of
lung cancer, two cases of stage I, two cases
of stage II, three cases of stage III, and one
case of stage IV cancer
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NSCLC-PBMC, while the CD4+ Tem cells outnumbered
the CD8+ Tem cells in NSCLC-Ly (p = 0.0049) (Fig. 1d).
Our results indicate that in human NSCLC patients, CD4+
and CD8+ T cell subsets show characteristic patterns of
distribution that differ among the tissues.
IFN-γ and TNF-α production is significantly decreased
in the naïve CD8 T cells of NSCLC patients
The striking differences in the function of naïve and mem-
ory T cells occur via the great diversity of cytokines pro-
duced within hours of stimulation. We examined whether
the functional capacities of the naïve CD4+ or CD8+ T
cells differed between NSCLC patients and the healthy
controls. After a short-term stimulation with PMA plus
ionomycin, the production of IFN-γ, TNF-α, and IL-17
was investigated. Only a small proportion (about 4%) of
the naïve CD4+ T cells from the blood of healthy donor
produced IFN-γ (Fig. 2a), and no significant difference
was observed between healthy donors and the NSCLC
patients in IFN-γ production by the CD4+ Tn cells from
the blood (Fig. 2b). The proportions of TNF-α-expressing
cells were observed in the CD4+ Tn cell population in the
blood of healthy donors (Fig. 2a). In contrast, in the pe-
ripheral blood of the NSCLC patients, the proportion of
TNF-α-expressing cells decreased to below 20%. There
were remarkably fewer CD8+ Tn cells that secreted
IFN-γ (p = 0.0158), TNF-α (p = 0.0121), or both in the
NSCLC-PBMC than in the HD-PBMC (Fig. 2b). We did
not detect IL-17 production from naïve CD4+ or CD8+ T
cells in the blood and lymph node of healthy donors and
NSCLC patients (Supplementary 1). There was no differ-
ence in the IFN-γ and TNF-α production of naïve T cells
between NSCLC-Ly and Normal-Ly (Fig. 2b). These re-
sults indicate that few of the naïve T cells in the blood
secrete IFN-γ. Naïve CD4+ T cells in the blood can se-
crete abundant TNF-α and were significantly increased
compared with naïve CD8+ T cells in healthy donor
(p = 0.0021), and the levels of TNF-α were significantly
decreased in the NSCLC patients (p = 0.0402) (Fig. 2c).
Negligible IL-17 production from the naïve T cells was
found for both sample types from the healthy donors and
the NSCLC patients.
Cytokine-expressing CD4+ Tcm cells are decreased
in blood of human NSCLC patients
A hallmark of memory T cells is their rapid recall response to
stimulation. In humans, the definition of Tcm and Tem cells is
based on two distinct criteria: the absence or presence of the
immediate effector function and the expression of homing re-
ceptors that allow the cells to migrate to secondary lymphoid
organs versus non-lymphoid tissues. Human Tcm cells are
CD45RO+CCR7+ cells and produce large amounts of IFN-γ,
IL-2, and IL-4 [2]. We examined the production of IFN-γ,
TNF-α, and IL-17 by the CD4+ or CD8+ Tcm cells in the blood
of the NSCLC patients after 4 h of stimulation with PMA plus
ionomycin (Fig. 3a). Higher frequencies of IFN-γ, TNF-α, and/
or dual-expressing CD4+ Tcm cells were observed in the blood
from the healthy donors, and similar proportions of cells that
produced these cytokines were observed in the CD8+ Tcm pop-
ulation (Fig. 3a). Compared to the NSCLC patients, the frequen-
cy of IFN-γ, TNF-α, and/or double-positive CD4+ Tcm cells in
the blood was higher in the healthy donors (p < 0.01) (Fig. 3b).
IL-17 production after PMA plus ionomycin stimulation was
observed, albeit at a low frequency; the fraction of IL-17-
secreting CD4+ Tcm cells was lower in NSCLC-PBMC than
in HD-PBMC (p = 0.0166) (Fig. 3b). We did not detect IL-17
expression in the CD8+ Tcm cells (Supplementary 2). The fre-
quency of the IFN-γ-expressing and TNF-α-expressing CD4+
Tcm cells was greater than that of IFN-γ-expressing
(p = 0.0007) and TNF-α-expressing CD8+ Tcm cells
(p = 0.002) in the HD-PBMC (Fig. 3c). Furthermore, there
was a higher proportion of IFN-γ-expressing CD8+ Tcm cells
in the NSCLC-Ly than in the Normal-Ly (p = 0.0038), and there
was a higher proportion of the IFN-γ-expressing and TNF-α-
expressing Tcm cells in the HD-PBMC (p = 0.0013) than in
Normal-Ly (p = 0.016) (Fig. 3b). Together, these results show
that the IFN-γ-expressing, TNF-α-expressing, and IL-17-
expressing CD4+ Tcm cells were significantly decreased in the
blood of the NSCLC patients.
IFN-γ-expressing CD8+Teff cells are remarkably reduced
in the blood of NSCLC patients
Effector cells secrete higher titers of cytokines than either
naïve or memory cells and with faster kinetics than the
Fig. 1 The distribution of CD4+ and CD8+ Tcells subsets in human lung
cancer. PBMCs were isolated from the blood of lung cancer patients and
healthy donors and analyzed by flow cytometry. a The frequency of the
CD3+CD4+ T cells and CD3+CD8+ T cells in the HD-PBMC, PBMCs
from healthy donors; NSCLC-PBMC, PBMCs from non-small lung
cancer patients, Normal-Ly, from healthy lymph node, NSCLC-Ly,
tumor infiltrated lymph node from non-small lung cancer patients. b
Representative flow cytometric analyses of CD45RA and CCR7
expression in CD3+CD4+ T cells and CD3+CD8+ T cells, indicating
naïve T cells (CD45RA+/CD45RO-CCR7+, top right quadrant),
terminal effector T cells (CD45RA+/CD45RO-CCR7-, bottom right
quadrant), central memory T cells (Tcm, CD45RO+/CD45RA-CCR7+,
top left quadrant), and effector memory T cells (Tem, CD45RO+/
CD45RA-CCR7-, bottom left quadrant), gated on the forward and side
scatter of the lymphocyte populations. c The frequency and absolute
number of the CD4+ (top) and CD8+ (bottom), Tn (middle gray), Teff
(black), Tcm (grey), and Tem (dark grey) cell subsets in the blood from
the non small cell lung cancer patients and healthy donors. d The events
of Tn, Teff, Tcm and Tem cell subsets of CD4+ and CD8+ cells in the
blood from non small cell lung cancer patients and healthy donors,
expressed as the mean ± SEM. *p < 0.05; **p < 0.005; ***p < 0.001;
Mann–Whitney test (two-tailed) and non-paired Student’s t-test
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resting T cell populations. IL-17 production in PMA plus
ionomycin-stimulated Teff cells was not observed in
PBMCs and lymph node from the healthy donors or the
NSCLC patients (Supplementary 3). IFN-γ and TNF-α
producers in the blood from the NSCLC patients repre-
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was significantly lower compared to the levels observed
in the blood from the healthy donors (p = 0.0061)
(p = 0.0001) (Fig. 4a, b). Whereas no difference was
observed in the proportion of IFN-γ-expressing and
TNF-α-expressing CD4+ Teff between NSCLC-PBMC
and HD-PBMC, TNF-α produced by the Teff cells signif-
icantly reduced in Normal-Ly than in HD-PBMC (CD4
group, p = 0.0096; CD8 group, p = 0.049); the frequency
of IFN-γ-expressing CD8+ Teff cells was also lower in
NSCLC-Ly than in NSCLC-PBMC (p = 0.035) (Fig. 4b).
There was no difference in the cytokine production be-
tween CD4+ Teff and CD8+ Teff in the lymph node and
blood (Fig. 4c). Our results therefore demonstrated differ-
ent patterns of functional CD8+ Teff cells in these tissue
sites; in particular, the production of TNF-α and IFN-γ by
the CD8+ Teff cells in PBMCs from the NSCLC patients
was significantly lower than that of the healthy donors.
The levels of IFN-γ-expressing, TNF-α-expressing,
and IL-17-expressing CD4+ Tem cells are decreased
in the blood of NSCLC patients
Compared with Tcm cells, Tem cells are characterized by a
rapid effector function. CD8+ Tem express large amounts of
perforin, and both CD4+ and CD8+ produce IFN-γ, IL-4, and
IL-5 within hours of antigenic stimulation. IL-17 is primarily
produced by the CD4+ Tem cells in the blood (Fig. 5a).
IFN-γ, TNF-α, IL-17, and/or dual expressors among the
CD4+ and CD8+ Tem cells were found to exceed those of
the CD4+ and CD8+ Teff cells in the blood (Fig. 5a). IFN-γ
and TNF-α producers of Tem cells were decreased in Normal-
Ly than in HD-PBMC (CD4 group, p ≤ 0.004; CD8 group,
p ≤ 0.01) (Fig. 5b). The levels of IFN-γ, TNF-α, and IL-17
cytokine-expressing CD4+ and CD8+ Tem cells were de-
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Fig. 2 IFN-γ and TNF-α production is significantly decreased in the
naïve CD8 T cells of NSCLC patients. PBMCs or lymphocytes isolated
from the blood were stimulated for 4-6 hr with PMA + Ionomycin, and
cytokine production was assessed by intracellular cytokine staining (ICS).
a Representative ICS analysis of cytokine production by CD4+
CD45RA+CCR7+ and CD4-/CD8+CD45RA+CCR7+ T cells in the
blood relative to the unstimulated controls. The numbers in the
quadrants indicate the percent of CD4+ T cells or CD8+ T cells that
produced IFN-γ, TNF-α, IL-17 or both cytokines. b The mean
IFN-γ and TNF-α production (±SEM) of the naïve CD4+ T cells (left)
and CD8+ Tcells (right) in the blood and lymph node from the non small
cell lung cancer patients and healthy donors. *p < 0.05; **p < 0.005; non-
paired Student’s t-test. c The events of IFN-γ, TNF-α–expressing CD4+
Tn and CD8+ Tn cells in the blood and lymph node from non small cell
lung cancer patients and healthy donors, expressed as the mean ±
SEM. *p < 0.05; ***p < 0.001; Mann–Whitney test (two-tailed) and
non-paired Student’s t-test
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the healthy donors (CD4 group, p ≤ 0.04; CD8 group,
p ≤ 0.003) (Fig. 5b, Supplementary 4). In the blood and lymph
node of the NSCLC patients, the proportion of cytokine-






















































































































































































































































































































































Fig. 3 Cytokine-expressing CD4+ Tcm cells are decreased in blood of
human NSCLC patients. a Flow cytometry plots showing IL-17, IFN-γ,
and TNF-α expression in the CD4+CD45RA−/CD45RO+CCR7+ and
CD4−/CD8+CD45RA−/CD45RO+CCR7+ T cells from the blood and
lymph node of the non-small cell lung cancer patients and healthy
donors. b The mean frequency (±SEM) of the IFN-γ-expressing, TNF-
α-expressing, and IL-17-expressing T cells gated on the CD4+ Tcm and
CD4−/CD8+ Tcm cells in the blood. c The graph shows the relative
frequencies of the cytokine-producing CD4+ Tcm and CD8+ Tcm cells
in the HD-PBMC, LC-PBMC, Normal-Ly, and NSCLC-Ly. *p < 0.05,
**p < 0.005, ***p < 0.001; non-paired Student’s t test
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same pattern (Fig. 5c). These results demonstrate that human
Tem cells are the primary source of IFN-γ, IL-17, and TNF-α
cytokine production. In the NSCLC patients, all of the exam-
ined cytokines produced by the Tem cells in the blood were
significantly decreased.
Discussion
In this study, we analyzed the distribution and functional ca-
pacity of the CD4+ and CD8+ T cell subsets in the blood and
lymph node of human NSCLC patients. The frequencies of
the CD8+ T cell subsets were similar for the blood and lymph
nodes of the NSCLC patients. The CD8+ Teff cells predom-
inated in both tissue sites, followed by the Tem, Tn, and Tcm
cells. However, the composition of the CD4+ T cell subsets
differed. The most one cell type was CD4+ Tn, followed by
Tem, Tcm, and Teff in the NSCLC-PBMC. The CD4+ Tem
cells were the major population in the NSCLC-Ly, followed
by the Tcm, Teff, and Tn cells. In the functional analysis, we
found that the levels of the IFN-γ-expressing CD8+ Tcm cells
were increased in the lymph nodes of the human NSCLC
patients. The capacity to express IFN-γ was remarkably re-
duced in the lymph nodes relative to the blood of the NSCLC
patients, even though the CD8+ Teff cells were present at a
higher frequency in the NSCLC patients than in the healthy
donors. The levels of IFN-γ-expressing, TNF-α-expressing,
and IL-17-expressing CD4+ Tem and CD4+ Tcm cells were
significantly decreased in the blood of the NSCLC patients
compared to healthy donors. We observed that all three of the
examined cytokines secreted by the CD4+ and CD8+ T cell
subsets were present at lower frequencies in the lymph node
than in the blood of the healthy donors. Our results showed
differences in the composition and function of the CD4+ and
CD8+ T cell subsets in the blood and lymph node of NSCLC
patients. The identification of these differences may improve
our understanding of the role of the T cell-mediated immune
response in antitumor immunity.
Different tissue locations and various types of human can-












































































































































































































































Fig. 4 IFN-γ-expressing CD8+ Teff cells are remarkably reduced in
blood of NSCLC patients. a IFN-γ and TNF-α dual expression by
CD4+CD45RA+CCR7− (left) and CD4−/CD8+CD45RA+CCR7−
(right) effector T cells in the blood and lymph node from non-small cell
lung cancer patients and healthy donors. b The mean IFN-γ and TNF-α
production (±SEM) in the cells from the blood of between healthy donor
and NSCLC patients. *p < 0.05, **p < 0.005, ***p < 0.001; non-paired
Student’s t test. c The percentage of IFN-γ-producing and TNF-α-
producing CD4+ Teff and CD8+ Teff cells in the blood and lymph
node from non-small cell lung cancer patients and healthy donors,












































a CD4+ Tem cell
HD-PBMC NSCLC-PBMC Normal-Ly NSCLC-Ly
HD-PBMC NSCLC-PBMC Normal-Ly NSCLC-Ly



































HD-PBMC NSCLC-PBMC Normal-Ly NSCLC-Ly
HD-PBMC NSCLC-PBMC Normal-Ly NSCLC-Ly

































































































































































































































































Fig. 5 The levels of IFN-γ-expressing, TNF-α-expressing, and IL-17-
expressing CD4+ Tem cells are decreased in the blood of NSCLC
patients. a IFN-γ, TNF-α, and IL-17 production by the CD4+ and
CD8+ Tem cells in the blood and lymph node, gated on the
unstimulated controls. The numbers in the quadrants indicate the
percent of the CD4+ T cells (left) or CD8+ T cells (right) that produce
IFN-γ, TNF-α, IL-17, or both cytokines. b The mean frequency (±SEM)
of the IFN-γ-expressing, TNF-α-expressing, and IL-17-expressing T
cells gated on the CD4+ Tem (left) and CD8+ Tem (right) T cells in the
blood. *p < 0.05, **p < 0.005, ***p < 0.001; Mann–Whitney test (two-
tailed) and non-paired Student’s t test. c The plot of IFN-γ-secreting and
TNF-α-secreting CD4+ Tem andCD8+Tem cells in the blood and lymph
node from non-small cell lung cancer patients and healthy donors,
expressed as the mean ± SEM
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showed that there was an increase in the effector CD8+ T
(CD8+CD27−CD45RA−) population in the peripheral blood
from head and neck carcinoma patients [15]. Another group
observed that there were no significant differences between
the effector CD8+ T cells (CD8+CD27−CD45RA−) in the
peripheral blood of healthy donors and lung adenocarcinoma
patients [16]. However, there was an elevated population of
memory (CD45RA−CD45RO+CD27+CD28+) CD8+ T cells
and a low proportion of terminally differentiated (CD45RA+
CD45RO−CD27−CD28−) CD8+ T cells in the pleural effu-
sions. These results are similar to the data from the TILs of
NSCLC patients in whom the CD4+ T cell subpopulation is
increased [10]. In our analysis of the CD8+ and CD4+ T cell
subsets in the blood and lymph node from NSCLC patients,
we identified the Tn, Tcm, Tem, and Teff cells according to
established surface markers [1, 6] in eight NSCLC patients.
We found that the levels of the Teff CD8+ T cells were signif-
icantly elevated in the blood from the NSCLC patients, and
these cells were also present in a higher frequency in the
lymph node. CD8+ T cells play an important role in the cell-
mediated antitumor immune response [17]. However, the role
of the CD8+ Teff cells in the lymph node is unclear. The
CD4+ T cell response is essential in preventing the induction
of tolerance by tumor antigens, and it helps the CD8+ T cells
differentiate into sustainable memory cells [12] that can initi-
ate antitumor immune responses. Importantly, the numbers of
CD4+ T cells are positively correlated with a favorable prog-
nosis in lung cancer patients [18]. Our results indicate that the
subtypes of the CD4+ and CD8+ Tm cells in NSCLC patients
are distinct, and a lower proportion of CD8+ Tcm cells, com-
pared to CD4+ Tcm cells, was found in both the peripheral
blood and the lymph node from NSCLC patients. In contrast,
a lower frequency of the CD8+ Tem cells, compared to the
CD4+ Tem cells, was observed only in the lymph node. The
mechanism by which CD4+ T cells aid in the formation of
CD8+ memory T cells remains unclear. CD4+ effector T cells
can mediate direct tumor destruction alone or with the help
from CD8+ Tcells [9, 18–20]. However, the role of the CD4+
memory T cell subsets in the antitumor response needs to be
further clarified. In humans, Tcm cells migrate to lymphoid
tissue, while Tem cells circulate to the non-lymphoid tissues
[2, 21, 22].We found that in the lymph node, the population of
the Tem cells was higher than that of the Tcm cells. The high
proportion of the Tem cells in the lymph node might be due to
a replenishment of the high frequency of recycling Teff cells.
TNF-α-expressing and IFN-γ-expressing naïve, memory,
and effector T cells were observed with low frequencies in the
blood of the NSCLC patients. IL-17 production was only
observed in the CD4+ Tcm and Tem cells of NSCLC subjects.
IFN-γ is the hallmark cytokine of Th1 cells and CD8+ T
cells, and it is critical for immune surveillance [23]. The func-
tion of the CD8+ T cells from lung cancer patients was im-
paired with respect to both Th1 cytokine production and
cytotoxic potential [23]. However, our results showed that
the proportion of the IFN-γ-producing CD8+ Tcm cells was
increased in the lymph node from the NSCLC patients. IFN-γ
production by the CD8+ Teff cells was significantly decreased
in the blood from the NSCLC patients, yet the number of
CD8+ Teff cells was increased. Tcm cells can differentiate into
Tem and Teff cells. It is possible that the CD8+ Tcm cells
replenish the Teff cells, leading to the high frequency of cir-
culating CD8+ Teff cells observed in the blood of the lung
cancer patients. In addition to IFN-γ, CD8+ Teff cells also
express the perforin, granzyme to kill tumor cells. Studies
have found that the IFN-γ-producing Th1 and CD8+ T cells
are more prone to apoptosis and are involved in the reduction
of the Teff cell populations [24, 25]. The IFN-γ-deficient
CD8+ T cells that expressed high levels of IL-7r were shown
to be the precursors of the memory cells. These cells block the
IFN-γ signaling pathway that contributes to the memory re-
sponses involved in tumor vaccination [26–28]. The role of
the IFN-γ-producing CD8+ Teff cells during the formation of
the CD8+ T memory cells in human lung cancer is less clear.
A role for inflammation in tumorigenesis is now generally
accepted, and it has become evident that an inflammatory
microenvironment is an essential component of all tumors
[29]. The cytokines in the tumor microenvironment can either
promote antitumor immunity (IL-12, IFN-γ), enhance tumor
development and progression (IL-6, IL-17, IL-23) [30], or
influence the cancer cell growth and survival (TRAIL, FasL,
TNF-α, TGF-β, IL-6). TNF-α in the bloodstream may have
oncogenic effects through several pathways, such as the stim-
ulation of the production of reactive oxygen species (ROS),
which can induce DNA damage and genomic instability; the
stimulation of stem cell-like tumor progenitors by promoting
β-catenin entry into the nucleus in inflammation-associated
gastric cancer [31]; and the promotion of MMP expression,
the invasiveness, and the survival of circulating metastatic
seeds via NF-κB and STAT3 [32, 33]. We found that the
frequency of TNF-α production in the Tcm, Tem, Tn, and
Teff cells from the blood of lung cancer patients is lower than
that of healthy donors. The low circulating levels of TNF-α in
the bloodstream might have beneficial effects in lung cancer
patients. Whether these low levels are one of the protective
mechanisms in human lung cancer needs to be verified.
The role of IL-17 in antitumor processes remains contro-
versial. Some studies have reported that the proportion of
Th17-producing cells was higher in multiple human cancers
and that these cells have a potent antitumor effect. This effect
might be related to the polyfunctional effector cytokines in-
duced by the IL-17 cells, specifically the induction of TNF-α,
IL-2, IFN-γ, and chemokines and the recruitment of NK cells
into the tumor microenvironment to target the tumor [34–36].
Other reports have shown that IL-17 induces tumor angiogen-
esis [37, 38] and that a high level of IL-17 is correlated with
advanced cancer [39]. Our current data revealed that IL-17
Immunol Res
was produced primarily by the CD4+ Tcm and CD4+ Tem
cells, not by other CD4+ and CD8+ T cell subsets, which is
consistent with the reports that 99% of the tumor-infiltrating
IL-17 T cells were IL-17 CD4+ (Th17) cells [40, 41]. In ad-
dition, the proportion of the IL-17 CD4+ memory T cells was
decreased in the blood from the NSCLC patients relative to
the healthy donors. The number of cells positive for dual cy-
tokines, including IL-17/IFN-γ and IL-17/TNF-α in the blood
of the NSCLC patients, was lower than in the healthy donors.
The effect of IL-17 production on the CD4+memory Tcells in
human lung cancer requires further investigation.
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